Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rodolfo Hurle

Showing results (151-160 of 183) with videos related to

Pageof 19
Sort By:
Translational Andrology and Urology|March 15, 2021
Systemic combining inflammatory score (SCIS): a new score for prediction of oncologic outcomes in patients with high-risk non-muscle-invasive urothelial bladder cancerMatteo Ferro, Marina Di Mauro, Sebastiano Cimino, et al.
Urologic Oncology|March 17, 2020
Type 2 diabetes mellitus predicts worse outcomes in patients with high-grade T1 bladder cancer receiving bacillus Calmette-Guérin after transurethral resection of the bladder tumorMatteo Ferro, Martha Orsolya Katalin, Carlo Buonerba, et al.
European Urology Oncology|June 4, 2019
Systemic Inflammatory Markers and Oncologic Outcomes in Patients with High-risk Non-muscle-invasive Urothelial Bladder CancerFrancesco Cantiello, Giorgio I Russo, Mihai Dorin Vartolomei, et al.
Urologic Oncology|June 8, 2022
Predictive clinico-pathological factors to identify BCG, unresponsive patients, after re-resection for T1 high grade non-muscle invasive bladder cancerMatteo Ferro, Biagio Barone, Felice Crocetto, et al.
World Journal of Urology|July 12, 2018
An increased body mass index is associated with a worse prognosis in patients administered BCG immunotherapy for T1 bladder cancerMatteo Ferro, Mihai Dorin Vartolomei, Giorgio Ivan Russo, et al.
BJU International|February 26, 2026
Impact of BCG failure patterns on efficacy of intravesical gemcitabine/docetaxel in high-risk non-muscle-invasive bladder cancerPietro Scilipoti, Paolo Zaurito, Mattia Longoni, et al.
Diagnostics (Basel, Switzerland)|March 25, 2022
Modified Glasgow Prognostic Score as a Predictor of Recurrence in Patients with High Grade Non-Muscle Invasive Bladder Cancer Undergoing Intravesical Bacillus Calmette-Guerin ImmunotherapyMatteo Ferro, Octavian Sabin Tătaru, Gennaro Musi, et al.
Journal of Cancer|December 7, 2018
Predictors of Residual T1 High Grade on Re-Transurethral Resection in a Large Multi-Institutional Cohort of Patients with Primary T1 High-Grade/Grade 3 Bladder CancerMatteo Ferro, Giuseppe Di Lorenzo, Carlo Buonerba, et al.
Urologic Oncology|February 26, 2022
Variant histologies in bladder cancer: Does the centre have an impact in detection accuracy?Alessia Cimadamore, Chiara Lonati, Ettore Di Trapani, et al.
Minerva Urology and Nephrology|October 5, 2022
Accuracy of the European Association of Urology (EAU) NMIBC 2021 scoring model in predicting progression in a large cohort of HG T1 NMIBC patients treated with BCGRoberto Contieri, Rodolfo Hurle, Marco Paciotti, et al.
Pageof 19

Showing results (151-160 of 183) with videos related to

Sort By:
Pageof 19
Translational Andrology and Urology|March 15, 2021
Systemic combining inflammatory score (SCIS): a new score for prediction of oncologic outcomes in patients with high-risk non-muscle-invasive urothelial bladder cancerMatteo Ferro, Marina Di Mauro, Sebastiano Cimino, et al.
Urologic Oncology|March 17, 2020
Type 2 diabetes mellitus predicts worse outcomes in patients with high-grade T1 bladder cancer receiving bacillus Calmette-Guérin after transurethral resection of the bladder tumorMatteo Ferro, Martha Orsolya Katalin, Carlo Buonerba, et al.
European Urology Oncology|June 4, 2019
Systemic Inflammatory Markers and Oncologic Outcomes in Patients with High-risk Non-muscle-invasive Urothelial Bladder CancerFrancesco Cantiello, Giorgio I Russo, Mihai Dorin Vartolomei, et al.
Urologic Oncology|June 8, 2022
Predictive clinico-pathological factors to identify BCG, unresponsive patients, after re-resection for T1 high grade non-muscle invasive bladder cancerMatteo Ferro, Biagio Barone, Felice Crocetto, et al.
World Journal of Urology|July 12, 2018
An increased body mass index is associated with a worse prognosis in patients administered BCG immunotherapy for T1 bladder cancerMatteo Ferro, Mihai Dorin Vartolomei, Giorgio Ivan Russo, et al.
BJU International|February 26, 2026
Impact of BCG failure patterns on efficacy of intravesical gemcitabine/docetaxel in high-risk non-muscle-invasive bladder cancerPietro Scilipoti, Paolo Zaurito, Mattia Longoni, et al.
Diagnostics (Basel, Switzerland)|March 25, 2022
Modified Glasgow Prognostic Score as a Predictor of Recurrence in Patients with High Grade Non-Muscle Invasive Bladder Cancer Undergoing Intravesical Bacillus Calmette-Guerin ImmunotherapyMatteo Ferro, Octavian Sabin Tătaru, Gennaro Musi, et al.
Journal of Cancer|December 7, 2018
Predictors of Residual T1 High Grade on Re-Transurethral Resection in a Large Multi-Institutional Cohort of Patients with Primary T1 High-Grade/Grade 3 Bladder CancerMatteo Ferro, Giuseppe Di Lorenzo, Carlo Buonerba, et al.
Urologic Oncology|February 26, 2022
Variant histologies in bladder cancer: Does the centre have an impact in detection accuracy?Alessia Cimadamore, Chiara Lonati, Ettore Di Trapani, et al.
Minerva Urology and Nephrology|October 5, 2022
Accuracy of the European Association of Urology (EAU) NMIBC 2021 scoring model in predicting progression in a large cohort of HG T1 NMIBC patients treated with BCGRoberto Contieri, Rodolfo Hurle, Marco Paciotti, et al.
Pageof 19